İsviçre - İtalyanca - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - olaparibum - compresse rivestite con film - olaparibum 150 mg, copovidonum k 28, silica colloidalis anhydrica, mannitolum, natrii stearylis fumaras corresp. natrium 0.354 mg, Überzug: hypromellosum, macrogolum 400, e 171, e 172 (flavum), e 172 (nigrum), pro compresso obducto. - onkologikum - synthetika

İsviçre - İtalyanca - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - ticagrelorum - compresse orodispersibili - ticagrelorum 90 mg, mannitolum, cellulosum microcristallinum, crospovidonum, xylitolum, calcii hydrogenophosphas, natrii stearylis fumaras, hydroxypropylcellulosum, silica colloidalis anhydrica, pro compresso corresp. natrium 0.53 mg. - inibizione piastrinica in combinazione con acido acetilsalicilico - synthetika

Avrupa Birliği - İtalyanca - EMA (European Medicines Agency)

astrazeneca ab - glycopyrronium, formoterol fumarate dihydrate - malattia polmonare, ostruttiva cronica - formoterolo e glycopyrronium bromuro - bevespi aerosphere è indicato come un broncodilatatore di mantenimento di trattamento per alleviare i sintomi in pazienti adulti con malattia polmonare ostruttiva cronica (bpco).

İsviçre - İtalyanca - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - benralizumabum - lnjektionslösung - benralizumabum 30 mg, histidinum, histidini hydrochloridum monohydricum, trehalosum dihydricum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - schweres eosinophiles asma - biotechnologika

İsviçre - İtalyanca - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - exenatidum - depot-lnjektionssuspension in einem autoinjektor - exenatidum 2 mg, saccharum, poly(lactidum-co-glycolidum) 50/50 (0.40 - 0.49 dl/g), triglycerida media, ad suspensionem pro dosi. - antidiabetico - synthetika

İsviçre - İtalyanca - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - acalabrutinibum - capsule rigide - acalabrutinibum 100 mg, cellulosum microcristallinum silicificatum, amylum pregelificatum, carboxymethylamylum natricum a corresp. natrium max. 0.25 mg, magnesii stearas, kapselhülle: gelatina, e 172 (flavum), e 132, e 171, drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammonii hydroxidum, pro capsula. - chronisch lymphatische leukämie (cll) - synthetika

Avrupa Birliği - İtalyanca - EMA (European Medicines Agency)

astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - agenti antineoplastici - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.

İsviçre - İtalyanca - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - budesonidum, glycopyrronium, formoteroli fumaras dihydricus - druckgasinhalation, suspension - budesonidum 160 µg, glycopyrronii bromidum 9 µg corresp. glycopyrronium 7.2 µg, formoteroli fumaras dihydricus 5 µg, 1,2-distearoyl-sn-glycero-3-phosphocholinum, calcii chloridum dihydricum, norfluranum, ad suspensionem pro dosi. - bpco - synthetika

Avrupa Birliği - İtalyanca - EMA (European Medicines Agency)

astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.

İsviçre - İtalyanca - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - tezepelumabum - soluzione iniettabile in siringa preriempita - tezepelumabum 210 mg, prolinum, acidum aceticum glaciale, polysorbatum 80, natrii hydroxidum q.s. ad ph, aqua ad iniectabile, ad solutionem pro 1.91 ml. - zusatztherapie bei schwerem asthma - biotechnologika